China's version of the precision medical plan will be launched

The National Health and Family Planning Commission reported on November 30 that my country is currently formulating a "precision medical" strategic plan, which may be included in the "13th Five-Year" major science and technology projects.

Precision medicine is mainly composed of top technologies such as gene sequencing, which will change the existing diagnosis and treatment models and bring a revolution to the development of medicine. According to reports, my country will develop a batch of domestic new prevention and treatment drugs and medical devices, form a batch of customized and internationally recognized disease diagnosis and treatment guidelines, clinical pathways and intervention measures, and significantly improve the level of prevention and treatment of major diseases., Diabetes, and rare diseases have formulated 8-10 precision treatment plans and promoted them nationwide.

Government attaches great importance
An official of the National Health and Family Planning Commission told a reporter from the China Securities Journal that the "precision medicine" strategic plan formulated this time is the National Health and Family Planning Commission, the Ministry of Science and Technology, the Chinese Academy of Sciences and other central ministries and commissions, in accordance with the instructions of the central leaders, and a group of top scientists. Research and formulation.
According to reports, after the relevant national ministries and commissions learned of the U.S. precision medical plan, they quickly submitted a special article on this plan to the national high-level, and the high-level immediately instructed the Ministry of Science and Technology to lead the investigation. The Ministry of Science and Technology encouraged the Beijing Institute of Genomics of the Chinese Academy of Sciences to conduct in-depth research in this field.
Regarding this top scientific research plan, the policy side has successively launched measures this year: On March 27 this year, my country released the first batch of high-throughput gene sequencing technology clinical pilot units for tumor diagnosis and treatment projects. On April 15, the National Health and Family Planning Commission and the Ministry of Science and Technology organized experts in the fields of biomedicine to discuss the precision medicine research plan with the Chinese Academy of Sciences and other departments. On May 10, the State Council issued the decision on canceling the examination and approval items of non administrative license, in which the 31st item is about canceling the approval of the clinical application of the third type of medical technology. The canceled approval items include the clinical application of the third type of medical technology, such as hematopoietic stem cell transplantation, gene chip diagnosis and immune cell therapy, which were originally responsible for by the national health and Family Planning Commission.
According to reports, the fastest action in the field of precision medicine is the UK. In 2012, the British government launched a large-scale sequencing research project-the "100000 Genome Project", which sequenced the complete genomes of 100000 patients in the British National Health Care System (NHS). The goal is to develop personalized based on genomics and clinical data. The treatment of cancer and rare diseases has made the NHS "the world's first mainstream health service system that will provide genomic medicine as part of daily care". So far, the UK has sequenced hundreds of genomes, with 10000 samples expected to be sequenced in 2016 and 100000 samples by 2017.

Big Data Analytics Escort
Precision medicine to achieve personality, efficiency and prevention, the premise is the disease screening and diagnosis. Therefore, to carry out precision medicine, the first thing is to develop gene sequencing and big data applications. From the perspective of the process of precision medicine, the industrial chain can be simply divided into two parts: diagnosis and treatment. The diagnostic process mainly involves the application of molecular diagnostic technology, big data and cloud computing, through the collection and detection of a single patient-related samples, and compared with the data of related diseases in the database, the relevant diagnostic results are obtained. In the treatment phase can be based on the results of the diagnosis of the implementation of the "amount of medicine".
Big data analytics will play a huge role in precision medicine. The premise of precise treatment is gene sequencing technology, and the data generated after gene sequencing depends on the comparison analysis of big data. A fully sequenced human genome contains 100GB-1000GB of data, which is very difficult to interpret and requires a special database for horizontal and vertical comparison analysis of data information. Many foreign companies have established their own large databases and developed related software for rapid data analysis. Myriad GEnetiCs, for example, has a proprietary database for the integrated analysis of big data that can be used to interpret uncertain genetic test results. Illumina company develops BAseSpace cloud computing and storage platform. SeVenBridges Genomics integrated cloud computing and NoSQL data technologies in human genome sequencing and analysis, and launched EC2, S3 and MongoDB.
Relying on its accumulated technical advantages in high-performance computing and large-capacity storage, Rongzhilian, a listed A- share company, designed, constructed and maintained bioinformatics supercomputing centers in Shenzhen and Hong Kong for BGI, successfully solving the problems of parallel computing and storage of massive data formed by gene sequencing. At present, BGI has a supercomputing capacity of 157 trillion runs per second, with a data storage capacity of 12.6PB, and its gene sequencing capacity ranks first in the world.
The information obtained after big data comparison analysis can provide guidance for individualized drug design and realize "quantitative medicine". At present, the most practical application significance of many predictive gene detection projects is "drug genotype detection", that is, targeted drugs are designed for human pathogenesis gene fragments, and big data is used to analyze the reaction, efficacy, sensitivity and side effects of the drugs, so as to screen out the best treatment method and individualized administration scheme. "Dosage genre medicine" will largely reduce clinical medication, improve efficacy and reduce medical costs, and point out the direction for future medicine.

Tumor detection market leading
In April this year, the National Health Planning Commission Medical Administration and Hospital Authority announced the list of the first batch of tumor high-throughput gene sequencing clinical application pilot units. It means that the genetic sequencing of tumor diseases has been approved by the regulatory authorities.
Daan Gene Holding Sun Company Guangzhou Daan Clinical Laboratory Center and Dean Diagnostics' wholly-owned subsidiary Hangzhou Dean Medical Laboratory Center were selected as the first batch of pilot units. The Health and Family Planning Commission pointed out that through pilot projects, we will do a good job in the verification and evaluation of high-throughput gene sequencing technology, gradually improve relevant technical specifications, and improve the application and management level of high-throughput gene sequencing technology in tumor diagnosis and treatment. In addition to the above two, the first batch of pilot units also include the Affiliated Cancer Hospital of Sun Yat sen University and Shenzhen Huada clinical testing center.
In 2006, the results of the third sampling survey on the causes of death of residents in my country showed that in the past 30 years, the mortality rate of breast cancer has increased by 96%, and the mortality rate of lung cancer has soared by 465. According to the "World Cancer Report" statistics, in 2012, the number of cancer cases in China was 3.065 million, accounting for about 1/5 of the global incidence; the number of cancer deaths was 2.205 million, accounting for about 1/4 of the global cancer deaths. For the treatment of such malignant diseases, on the one hand, it is to increase the breakthrough in the research and development of therapeutic drugs, on the other hand, it should make a breakthrough in treatment technology from the perspective of precise treatment.
According to industry insiders, the current tumor treatment is gradually changing from the macro level of "disease" medication to a more micro level of gene medication, realizing "different treatment of the same disease" or "same treatment of different diseases". Precision treatment has become a recognized trend of tumor treatment. In view of the broad prospects of the tumor gene sequencing market, following the battle for non-invasive prenatal sequencing for several years, a number of domestic gene companies began to enter the tumor detection market, began to compete for this big cake.
Previously, the National Health and Family Planning Commission only approved the Xiangya Medical Laboratory of Central South University, Beijing Boao Medical Laboratory and the First Affiliated Hospital of China Medical University. All three were government backgrounds and the progress was slow. With the National Health Planning Commission announced the first batch of tumor high-throughput gene sequencing clinical application pilot at the end of March, individual companies have been strong. the development of huada gene qixia huada medicine is the fastest, and tumor detection is one of the "death" strategies in the "life and death strategy" strategy of huada medicine.
The tumor package of Huada Medical has been released recently and is being put on the market. The target customers include not only healthy people, high-risk groups, but also auxiliary treatment and prognosis monitoring. This package involves the type of tumor is currently the most comprehensive in the Chinese market. Healthy and high-risk groups are suitable for "hereditary tumor screening", including 15 kinds of common tumors in men and 16 kinds of common tumors in women. Common cancers such as breast cancer, ovarian cancer and lung cancer are all within the scope of the package; patients suffering from tumors are suitable for individualized treatment package, which is targeted at targeted medication, prognosis and recurrence monitoring, etc.

(Information from the small orange lamp network)